BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11935694)

  • 1. [Borderline ovarian tumors].
    Ivanov S
    Akush Ginekol (Sofiia); 2002; 42(1):23-5. PubMed ID: 11935694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
    Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?
    Benito V; Lubrano A; Arencibia O; Medina N; Álvarez Eva E; Andújar M; Falcón Juan M; Falcón O
    Eur J Obstet Gynecol Reprod Biol; 2010 Dec; 153(2):188-92. PubMed ID: 20728981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
    Saygili U; Uslu T; Erten O; Doğan E
    Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
    Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in studies of ovarian serous and mucinous borderline ovarien tumors].
    Shao HL; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):173-5. PubMed ID: 16630508
    [No Abstract]   [Full Text] [Related]  

  • 13. Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern.
    Laurent I; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
    BJOG; 2009 May; 116(6):860-2. PubMed ID: 19432576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
    Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
    Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy.
    Ødegaard E; Staff AC; Langebrekke A; Engh V; Onsrud M
    Acta Obstet Gynecol Scand; 2007; 86(5):620-6. PubMed ID: 17464594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sharing antigenic determinant of colon carcinoma between serous and mucinous tumors of the ovary].
    Liu MP; Lu ZT; Chen W
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):398-400, 444. PubMed ID: 7528120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The dose-response of cell proliferation and secretion of CA125 II antigen to follicle stimulating hormone in ovarian cancer cell lines].
    Zhu M; Wu Q; Ge B
    Zhonghua Fu Chan Ke Za Zhi; 1998 Apr; 33(4):225-6. PubMed ID: 10682470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.